Previous Phase I and proof of concept studies of ganaxolone have demonstrated safety and efficacy in refractive epilepsy. The ganaxolone program currently consists of four clinical studies, one infantile spasms and one adult partial seizure study as well as open label extensions for each study.
John Krayacich, CEO of Marinus, said: “Completion of the infantile spasms study and the completion of recruitment in the adult partial seizure trial are significant milestones for the ganaxolone program.
“We are anxious to review the unblinded data in the infantile spasms study and hope to present the data to the medical community early in 2009. We anticipate the data in the adult study to be available in the first half of 2009 and to present the data in the second half of 2009.”